Background
Phase 3 open-label RCT (SQUIRE); N=1,093 stage IV squamous NSCLC. Necitumumab is a recombinant human IgG1 anti-EGFR monoclonal antibody.
Interventions and follow up
Arm A: Gemcitabine 1,250 mg/m2 (d1,8) + cisplatin 75 mg/m2 (d1) + necitumumab 800 mg (d1,8) IV q3w x6 cycles, then necitumumab maintenance until progression
Arm B: Gemcitabine 1,250 mg/m2 + cisplatin 75 mg/m2 IV q3w x6 cycles
Primary endpoint: overall survival
mFollow up: 25.2mo
Arm B: Gemcitabine 1,250 mg/m2 + cisplatin 75 mg/m2 IV q3w x6 cycles
Primary endpoint: overall survival
mFollow up: 25.2mo
Results
mOS: 11.5mo vs 9.9mo, arm A vs B; HR 0.84, 95%CI 0.74-0.96; P=.01
1-yr OS: 48% vs 43%
2-yr OS: 20% vs 17%
1-yr OS: 48% vs 43%
2-yr OS: 20% vs 17%
Adverse events
Overall: Grade 3-4 events more frequent with necitumumab; discontinuation 31% vs 25%
Cardiac (boxed warning): cardiopulmonary arrest 3% vs 0.6%
Metabolic (boxed warning): hypomagnesemia 83% vs 70%
Thrombotic: VTE+ATE 9% vs 5%; grade ≥3 VTE 5% vs 3%; ATE 5% vs 4%, grade ≥3 ATE 4% vs 2%
Cardiac (boxed warning): cardiopulmonary arrest 3% vs 0.6%
Metabolic (boxed warning): hypomagnesemia 83% vs 70%
Thrombotic: VTE+ATE 9% vs 5%; grade ≥3 VTE 5% vs 3%; ATE 5% vs 4%, grade ≥3 ATE 4% vs 2%
Conclusions
Adding necitumumab to cisplatin/gemcitabine modestly improved OS in advanced squamous NSCLC but at the cost of meaningful toxicity.
Key Limitations
Absolute OS gain only ~1.6 months; substantial added toxicity (boxed warnings for cardiopulmonary arrest and hypomagnesemia) and cost; no benefit in non-squamous histology.
Clinical Context
FDA approved 2015 for 1L squamous NSCLC with cisplatin/gemcitabine; subsequently removed from ESMO/major guideline recommendations given marginal benefit, toxicity, and cost, and superseded by chemo-immunotherapy regimens (e.g., KEYNOTE-407). Largely obsolete.